CAS 952652-79-8

Formule : C23H27N5O3

InChI : InChI=1S/C23H27N5O3/c1-4-7-20(29)28(21(15(2)3)23(30)31)14-16-10-12-17(13-11-16)18-8-5-6-9-19(18)22-24-26-27-25-22/h5-6,8-13,15,21H,4,7,14H2,1-3H3,(H,30,31)(H,24,25,26,27)/t21-/m0/s1

Code InChI : OKAQHVJSXLGXET-NRFANRHFSA-N

SMILES : CCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O

Valsartan Related Compound B

CAS : 952652-79-8

Heterocyclic compounds with nitrogen hetero-atom(s) only, aromatic or modified aromatic, nesoi

Formule : C₂₃H₂₇N₅O₃

Couleur et forme : White Powder

Masse moléculaire : 421.21139

Ref: 45-1708784

(S)-2-(N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)butyramido)-3-methylbutanoic acid

CAS : 952652-79-8

(S)-2-(N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)butyramido)-3-methylbutanoic acid

Formule : C₂₃H₂₇N₅O₃

Degré de pureté : 95%

Masse moléculaire : 421.49

Ref: 54-OR1124846

Valsartan EP Impurity C (Valsartan USP Related Compound B)

CAS : 952652-79-8

Formule : C₂₃H₂₇N₅O₃

Couleur et forme : Off-White Solid

Masse moléculaire : 421.50

Ref: 4Z-V-026

(S)-2-(N-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)butyramido)-3-methylbutanoic acid

CAS : 952652-79-8

Formule : C₂₃H₂₇N₅O₃

Degré de pureté : 95%

Couleur et forme : Solid

Masse moléculaire : 421.4922

Ref: IN-DA00IIWL

(2S)-2-[Butanoyl[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]amino]-3-methylbutanoic Acid

CAS : 952652-79-8

Formule : C₂₃H₂₇N₅O₃

Couleur et forme : Neat

Masse moléculaire : 421.49

Ref: 86-MM0487.04

Valsartan n-Propyl Impurity

Produit contrôlé

CAS : 952652-79-8

Impurity Valsartan Related Compound B
Applications Valsartan n-Propyl is an impurity in the synthesis of Valsartan (V095750). Valsartan USP Related Compound B.
References Hillaert, S., et al.: J. Pharm. Biomed. Anal., 31, 329 (2003), Carlucci, G., et al.: Anal. Lett., 33, 2491 (2000), Cagigal, E., et al.: Talanta, 54, 1121 (2001),

Formule : C₂₃H₂₇N₅O₃

Couleur et forme : Neat

Masse moléculaire : 421.49

Ref: TR-V095770

Valsartan Impurity 46

CAS : 952652-79-8

Formule : C₂₅H₃₁N₅O₃

Couleur et forme : Off-White Solid

Masse moléculaire : 449.56

Ref: 4Z-V-0268

Valsartan EP Impurity C

CAS : 952652-79-8

Formule : C₂₃H₂₇N₅O₃

Masse moléculaire : 421.49

Ref: ST-EA-CP-V3003

(S)-N-Butyryl-N-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]valine

CAS : 952652-79-8

(S)-2-(N-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)butyramido)-3-methylbutanoic acid

Formule : C₂₃H₂₇N₅O₃

Degré de pureté : 98%

Masse moléculaire : 421.49

Ref: IN-DG164353

N-(1-Oxobutyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine

CAS : 952652-79-8

N-(1-Oxobutyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine (GW1929) is a potent vasodilator that is used for the treatment of hypertension. It is synthesized by condensation of sodium hydroxide with 2-(4′-chlorophenyl)piperazine followed by methyl esterification and chloride acylation. The synthesis of GW1929 has been accomplished in two steps: carbonate cyclization and valsartan hydrolysis. In the first step, the carboxylic acid group of GW1929 was converted to its corresponding chloride compound which was then reacted with methyl bromide to yield the desired product. The second step involved hydrolysis of GW1929 with potassium carbonate, after which it was oxidized with azide to form an ester. Sodium

Formule : C₂₃H₂₇N₅O₃

Degré de pureté : Min. 95%

Couleur et forme : White Powder

Masse moléculaire : 421.49 g/mol

Ref: 3D-IO28664